Q1 EPS Forecast for Summit Therapeutics Decreased by Analyst

Summit Therapeutics Inc. (NASDAQ:SMMT) – Analysts at HC Wainwright reduced their Q1 2025 earnings per share (EPS) estimates for Summit Therapeutics in a research report issued to clients and investors on Tuesday, February 25th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($0.09) per share for the quarter, down from their previous forecast of ($0.08). HC Wainwright has a “Buy” rating and a $44.00 price objective on the stock. The consensus estimate for Summit Therapeutics’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Summit Therapeutics’ Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.39) EPS.

A number of other analysts have also recently weighed in on the company. StockNews.com cut Summit Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. Wells Fargo & Company initiated coverage on Summit Therapeutics in a report on Wednesday, December 11th. They issued an “overweight” rating and a $30.00 price target for the company. Truist Financial began coverage on shares of Summit Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $35.00 price objective on the stock. JMP Securities assumed coverage on shares of Summit Therapeutics in a research report on Monday, November 4th. They issued a “market outperform” rating and a $32.00 price objective for the company. Finally, Jefferies Financial Group began coverage on shares of Summit Therapeutics in a research report on Friday, December 6th. They set a “buy” rating and a $31.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $33.57.

Summit Therapeutics Stock Up 1.0 %

Shares of SMMT opened at $18.49 on Friday. The company has a 50 day moving average of $19.93 and a two-hundred day moving average of $19.19. The company has a market cap of $13.64 billion, a price-to-earnings ratio of -66.03 and a beta of -0.88. Summit Therapeutics has a twelve month low of $2.10 and a twelve month high of $33.89.

Summit Therapeutics (NASDAQ:SMMT) last issued its quarterly earnings data on Monday, February 24th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.08). The firm had revenue of $0.20 million during the quarter.

Institutional Investors Weigh In On Summit Therapeutics

Large investors have recently bought and sold shares of the company. Darwin Wealth Management LLC purchased a new position in Summit Therapeutics during the 3rd quarter worth approximately $25,000. Covestor Ltd increased its stake in shares of Summit Therapeutics by 2,767.4% in the third quarter. Covestor Ltd now owns 1,233 shares of the company’s stock worth $27,000 after acquiring an additional 1,190 shares during the period. Brooklyn Investment Group purchased a new position in shares of Summit Therapeutics during the fourth quarter worth $29,000. National Bank of Canada FI acquired a new position in Summit Therapeutics during the fourth quarter valued at $30,000. Finally, Steward Partners Investment Advisory LLC boosted its holdings in Summit Therapeutics by 56.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,503 shares of the company’s stock valued at $45,000 after purchasing an additional 900 shares during the last quarter. Hedge funds and other institutional investors own 4.61% of the company’s stock.

Summit Therapeutics Company Profile

Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.